US regulatory status: approved.
biotech · Presbyopia · Eye Diseases · LENZ
LENZ Therapeutics
LENZ Therapeutics drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
San Diego, USA HQ
176 Employees
Public company Type
LENZ · NYSE Ticker
Company details
- Status
- Public
- HQ
- San Diego, USA
- Employees
- 176
- Programs
- 5
- Drugs
- 6
- Patents
- 20
LENZ Therapeutics pipeline
Portfolio lens on 6 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
LENZ Therapeutics drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
brimonidine
Dermatologicals (D11)Dermatologicals (D11) compound in LENZ Therapeutics's portfolio. Mechanism: Adrenergic receptor alpha-2 agonist.
- Mechanism
- Adrenergic receptor alpha-2 agonist
-
Development asset linked to LENZ Therapeutics in public FDA and regional records.
-
Development asset linked to LENZ Therapeutics in public FDA and regional records.
-
Development asset linked to LENZ Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M3.
- Target
- Muscarinic acetylcholine receptor M3
- Mechanism
- Muscarinic acetylcholine receptor M3 antagonist